Mackenzie Financial’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $709K | Buy |
+37,827
| New | +$709K | ﹤0.01% | 1112 |
|
|
2024
Q2 | – | Sell |
-4,767
| Closed | -$70.6K | – | 1607 |
|
|
2024
Q1 | $70.6K | Buy |
4,767
+1,279
| +37% | +$18.9K | ﹤0.01% | 1457 |
|
|
2023
Q4 | $50.6K | Buy |
3,488
+176
| +5% | +$2.55K | ﹤0.01% | 1446 |
|
|
2023
Q3 | $33.8K | Buy |
3,312
+402
| +14% | +$4.1K | ﹤0.01% | 1435 |
|
|
2023
Q2 | $38.1K | Hold |
2,910
| – | – | ﹤0.01% | 1475 |
|
|
2023
Q1 | $38.4K | Sell |
2,910
-475
| -14% | -$6.27K | ﹤0.01% | 1457 |
|
|
2022
Q4 | $50.8K | Buy |
3,385
+351
| +12% | +$5.27K | ﹤0.01% | 1351 |
|
|
2022
Q3 | $36K | Sell |
3,034
-459
| -13% | -$5.45K | ﹤0.01% | 1382 |
|
|
2022
Q2 | $39K | Buy |
3,493
+1,496
| +75% | +$16.7K | ﹤0.01% | 1410 |
|
|
2022
Q1 | $60K | Hold |
1,997
| – | – | ﹤0.01% | 1365 |
|
|
2021
Q4 | $53K | Sell |
1,997
-73
| -4% | -$1.94K | ﹤0.01% | 1398 |
|
|
2021
Q3 | $75K | Buy |
2,070
+417
| +25% | +$15.1K | ﹤0.01% | 1386 |
|
|
2021
Q2 | $72K | Buy |
1,653
+583
| +54% | +$25.4K | ﹤0.01% | 1200 |
|
|
2021
Q1 | $37K | Sell |
1,070
-140
| -12% | -$4.84K | ﹤0.01% | 1115 |
|
|
2020
Q4 | $42K | Hold |
1,210
| – | – | ﹤0.01% | 1028 |
|
|
2020
Q3 | $29K | Sell |
1,210
-200
| -14% | -$4.79K | ﹤0.01% | 973 |
|
|
2020
Q2 | $26K | Buy |
+1,410
| New | +$26K | ﹤0.01% | 993 |
|
|
2018
Q2 | – | Sell |
-7,718
| Closed | -$273K | – | 1050 |
|
|
2018
Q1 | $273K | Buy |
7,718
+1,312
| +20% | +$46.4K | ﹤0.01% | 827 |
|
|
2017
Q4 | $249K | Buy |
6,406
+1,909
| +42% | +$74.2K | ﹤0.01% | 776 |
|
|
2017
Q3 | $114K | Buy |
4,497
+646
| +17% | +$16.4K | ﹤0.01% | 609 |
|
|
2017
Q2 | $105K | Buy |
3,851
+2,151
| +127% | +$58.6K | ﹤0.01% | 607 |
|
|
2017
Q1 | $56K | Buy |
+1,700
| New | +$56K | ﹤0.01% | 626 |
|